U.S. Life Sciences Stock News

NYSE:ATMU
NYSE:ATMUMachinery

Atmus Filtration Technologies (ATMU) Margin Expansion Reinforces Bullish Earnings Narratives

Atmus Filtration Technologies (ATMU) has capped FY 2025 with Q4 revenue of US$446.6 million and basic EPS of US$0.59. Trailing twelve month revenue landed at US$1.76 billion with EPS of US$2.52 and net income of US$207.4 million. The company has seen quarterly revenue move from US$403.7 million and EPS of US$0.53 in Q3 2024 to the current Q4 2025 levels. Trailing twelve month EPS has stepped up from US$2.16 to US$2.52 over the same comparison points, setting up a results season where...
NYSE:RPC
NYSE:RPCCapital Markets

Ridgepost Capital (RPC) Valuation Check After Rebrand And High P/E Versus Peers

Why Ridgepost Capital Is On Investors’ Radar Ridgepost Capital (RPC) recently rebranded from P10, Inc. This shift is putting fresh attention on how this multi asset class private market solutions provider is positioned across private equity, venture capital, impact investing, and private credit. See our latest analysis for Ridgepost Capital. At a latest share price of $8.70, Ridgepost Capital has seen a 2.35% 1 day share price return. Its 30 day share price return of 18.77% and 1 year total...
NYSE:AKR
NYSE:AKRRetail REITs

Acadia Realty Trust (AKR) FFO Stability Reinforces Bullish Urban Retail Narratives

Acadia Realty Trust (AKR) has wrapped up FY 2025 with fourth quarter revenue of US$106.7 million and basic EPS of US$0.04, alongside funds from operations of US$41.6 million, which is a key earnings gauge for REIT investors. The company has seen quarterly revenue move from US$92.8 million in Q4 2024 to US$106.7 million in Q4 2025, while basic EPS shifted from US$0.07 to US$0.04 over the same period. Investors may now weigh the solid top line momentum against margins that are likely to be...
NasdaqCM:NEO
NasdaqCM:NEOHealthcare

NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance

NeoGenomics, NasdaqCM:NEO, has launched PanTracer Pro, a new diagnostic solution for clinicians treating advanced stage solid tumors. The offering combines broad genomic profiling and customized diagnostic testing into a single order with a focus on faster turnaround times. PanTracer Pro is designed to address fragmented testing workflows, treatment delays, and incomplete biomarker assessment in cancer care. NeoGenomics, trading at $11.38, has seen mixed share price performance, with a 30...
NYSE:NSC
NYSE:NSCTransportation

Norfolk Southern Union Pacific Merger Reshapes Rail Network And Risk Profile

Norfolk Southern (NYSE:NSC) has entered into a merger agreement with Union Pacific to form what is described as America's first transcontinental railroad. The transaction comes while Norfolk Southern continues to face legal proceedings related to the 2023 East Palestine incident. These developments are expected to affect the company's operations, regulatory profile, and position within the North American rail industry. For investors watching Norfolk Southern at a share price of $314.94,...
NYSE:MH
NYSE:MHConsumer Services

Is McGraw Hill (MH) Pricing Reflect Its Recent Share Price Weakness And Cash Flow Outlook

If you are asking yourself whether McGraw Hill is priced attractively right now, this article will walk through what the current share price might be implying about the business. The stock last closed at US$13.67, with a recent 7 day return of 8.3%, a 30 day return of 5.7% decline, and a year to date return of 16.4% decline, which may have caught your eye if you are watching for changing risk and reward. Recent evergreen coverage interest around McGraw Hill has focused on how the market is...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences (EXAS) Loss Rebound In Q4 Challenges Profitability Progress Narrative

Exact Sciences (EXAS) just reported its FY 2025 numbers with fourth quarter revenue of US$878.4 million, a basic EPS loss of US$0.45 and net income loss of US$86.0 million, while on a trailing twelve month basis revenue came in at about US$3.2 billion with a basic EPS loss of US$1.10 and a net income loss of US$207.9 million. The company has seen quarterly revenue move from US$713.4 million in Q4 2024 to US$878.4 million in Q4 2025, with basic EPS losses over that span ranging from US$4.67 to...
NasdaqGS:SBRA
NasdaqGS:SBRAHealth Care REITs

Sabra Health Care REIT Shifts CIO As Senior Housing Growth Accelerates

Sabra Health Care REIT (NasdaqGS:SBRA) has appointed Darrin Smith as Chief Investment Officer, Secretary, and Executive Vice President following the retirement of Talya Nevo-Hacohen. The company reports strong operational execution, with gains in occupancy, NOI, and margin within its senior housing portfolio. Sabra highlights an investment pipeline for 2026 that it expects to exceed already high 2025 levels. Sabra Health Care REIT, trading at around $20.17, enters this management transition...
NYSE:PHIN
NYSE:PHINAuto Components

PHINIA Growth Story Links 2025 Execution With 2026 Transition Goals

PHINIA Inc. (NYSE:PHIN) reported year over year growth across key business segments in 2025. The company recorded three consecutive quarters of growth in both Fuel Systems and Aftermarket segments. Management reduced debt, improved leverage, and expressed optimism for 2026. Leadership is targeting further market share gains in areas such as Gasoline Direct Injection and alternative fuels. PHINIA, trading as NYSE:PHIN, focuses on Fuel Systems and Aftermarket products that support internal...